A new trading day began on Friday, with Black Diamond Therapeutics Inc (NASDAQ: BDTX) stock price down -5.32% from the previous day of trading, before settling in for the closing price of $1.88. BDTX’s price has ranged from $1.59 to $7.66 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 43.16%. With a float of $43.16 million, this company’s outstanding shares have now reached $56.64 million.
The firm has a total of 24 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Black Diamond Therapeutics Inc (BDTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Black Diamond Therapeutics Inc is 23.83%, while institutional ownership is 64.85%. The most recent insider transaction that took place on Mar 19 ’25, was worth 11,997,749. In this transaction 10% Owner of this company sold 5,784,292 shares at a rate of $2.07, taking the stock ownership to the 2,733,547 shares. Before that another transaction happened on Aug 28 ’24, when Company’s 10% Owner sold 221,600 for $6.32, making the entire transaction worth $1,400,556. This insider now owns 3,726,341 shares in total.
Black Diamond Therapeutics Inc (BDTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.71% during the next five years compared to -5.22% drop over the previous five years of trading.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
Here are Black Diamond Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.27, a number that is poised to hit 0.05 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Analysing the last 5-days average volume posted by the [Black Diamond Therapeutics Inc, BDTX], we can find that recorded value of 28.7 million was better than the volume posted last year of 3.42 million. As of the previous 9 days, the stock’s Stochastic %D was 16.73%. Additionally, its Average True Range was 0.23.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 10.27%, which indicates a significant decrease from 15.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 80.91% in the past 14 days, which was higher than the 75.91% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.1484, while its 200-day Moving Average is $3.7037. Now, the first resistance to watch is $1.8500. This is followed by the second major resistance level at $1.9200. The third major resistance level sits at $2.0100. If the price goes on to break the first support level at $1.6900, it is likely to go to the next support level at $1.6000. Should the price break the second support level, the third support level stands at $1.5300.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
With a market capitalization of 100.86 million, the company has a total of 56,662K Shares Outstanding. Currently, annual sales are 0 K while annual income is -69,680 K. The company’s previous quarter sales were 0 K while its latest quarter income was -15,990 K.
